VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026.

businesswire.com - 2026-07-07 16:05:00

Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-07-07 13:01:15

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Lynn Seely to its Board of Directors.

businesswire.com - 2026-07-06 09:00:00

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

zacks.com - 2026-07-03 10:41:15

ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-06-25 09:46:08

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

zacks.com - 2026-06-18 11:31:04

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.

benzinga.com - 2026-06-17 12:54:55

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

zacks.com - 2026-06-17 10:40:28

Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop ​T-cell engaging multispecific antibodies for cancer, the ‌companies said on Wednesday.

reuters.com - 2026-06-17 07:43:56

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from the collaboration DUBLIN and VANCOUVER, BC, June 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.

prnewswire.com - 2026-06-17 07:00:00

DUBLIN & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies.

businesswire.com - 2026-06-17 07:00:00

AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions.

seekingalpha.com - 2026-06-17 06:33:06

AbCellera Biologics Inc. remains rated Hold, with valuation concerns outweighing near-term pipeline catalysts despite recent share price volatility. ABCL635, targeting hot flashes, is advancing to a Phase 2 trial with a key data readout expected in Q3, potentially derisking the program. Partnered and proprietary pipeline programs lack momentum, with most assets preclinical or awaiting external funding, limiting near-term revenue visibility.

seekingalpha.com - 2026-06-09 09:18:17

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com - 2026-06-08 10:56:33

AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-05 15:12:58

[url="]AbCellera[/url] (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. “Dr.

gurufocus.com - 2026-06-05 10:00:00

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Victor Sandor to its Board of Directors.

businesswire.com - 2026-06-05 09:00:00

AbCellera Biologics NASDAQ: ABCL is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech's pipeline and lead clinical program.

marketbeat.com - 2026-06-04 13:02:53

Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

zacks.com - 2026-06-01 10:42:32

From a technical perspective, AbCellera Biologics Inc. (ABCL) is looking like an interesting pick, as it just reached a key level of support. ABCL's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

zacks.com - 2026-05-29 10:55:17

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com - 2026-05-22 10:56:15

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.

247wallst.com - 2026-05-18 07:35:19

Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

zacks.com - 2026-05-14 10:41:28

AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-14 00:20:47

AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-12 06:27:02

AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years.

marketbeat.com - 2026-05-11 19:08:05

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.15 per share a year ago.

zacks.com - 2026-05-11 18:25:27

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.

businesswire.com - 2026-05-11 16:05:00

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.

businesswire.com - 2026-04-20 09:00:00